Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,715 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis).
Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, Dytfeld D, Angelucci E, Vincent L, Perrot A, Benjamin R, van de Donk NWCJ, Ocio EM, Roccia T, Schecter JM, Koskinen S, Haddad I, Strulev V, Mitchell L, Buyze J, Filho OC, Einsele H, Moreau P. Mateos MV, et al. Among authors: moreau p. Leukemia. 2024 Dec;38(12):2554-2560. doi: 10.1038/s41375-024-02404-6. Epub 2024 Sep 25. Leukemia. 2024. PMID: 39322709 Free PMC article.
The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement.
Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group. Hussein MA, et al. Leukemia. 2008 Aug;22(8):1479-84. doi: 10.1038/leu.2008.127. Epub 2008 May 29. Leukemia. 2008. PMID: 18509352 No abstract available.
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. Dispenzieri A, et al. Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. Leukemia. 2009. PMID: 19020545 Review.
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG. Giralt S, et al. Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25. Leukemia. 2009. PMID: 19554029
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Kyle RA, et al. Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. Leukemia. 2010. PMID: 20410922 Free PMC article. Review.
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphoma.
Clavert A, Le Gouill S, Brissot E, Dubruille V, Mahe B, Gastinne T, Blin N, Chevallier P, Guillaume T, Delaunay J, Ayari S, Saulquin B, Moreau A, Moreau P, Harousseau JL, Milpied N, Mohty M. Clavert A, et al. Among authors: moreau p, moreau a. Leuk Lymphoma. 2010 Aug;51(8):1502-8. doi: 10.3109/10428194.2010.497981. Leuk Lymphoma. 2010. PMID: 20583964 Clinical Trial.
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M. Malard F, et al. Among authors: moreau p. Biol Blood Marrow Transplant. 2011 Nov;17(11):1698-703. doi: 10.1016/j.bbmt.2011.04.010. Epub 2011 May 3. Biol Blood Marrow Transplant. 2011. PMID: 21601642 Free article.
1,715 results